ketorolac has been researched along with Pseudophakia in 5 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Pseudophakia: Presence of an intraocular lens after cataract extraction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate whether ketorolac ophthalmic drops prescribed four times a day can be associated with improved visual acuity and prompt resolution of edema for patients with pseudophakic cystoid macular edema identified more than 24 months after cataract surgery." | 9.09 | Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. ( Bressler, NM; Bressler, SB; Schachat, AP; Weisz, JM, 1999) |
| "To assess the effectiveness of ketorolac vs control for prevention of acute pseudophakic cystoid macular edema (CME)." | 8.88 | Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. ( Cordero-Coma, M; Gallagher, MJ; Yilmaz, T, 2012) |
| "Although NSAID therapy seems to potentiate the improvements produced by corticosteroids and antivascular endothelial growth factor therapy for chronic pseudophakic cystoid macular edema, only nepafenac- and bromfenac-treated eyes showed reduced retinal thickness at 12 weeks and 16 weeks." | 5.14 | NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. ( Bahrani, H; Fox, JE; Warren, KA, 2010) |
| "To evaluate whether ketorolac ophthalmic drops prescribed four times a day can be associated with improved visual acuity and prompt resolution of edema for patients with pseudophakic cystoid macular edema identified more than 24 months after cataract surgery." | 5.09 | Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. ( Bressler, NM; Bressler, SB; Schachat, AP; Weisz, JM, 1999) |
| "To assess the effectiveness of ketorolac vs control for prevention of acute pseudophakic cystoid macular edema (CME)." | 4.88 | Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. ( Cordero-Coma, M; Gallagher, MJ; Yilmaz, T, 2012) |
| "To determine the rate of postoperative cystoid macular edema (CME) in patients undergoing cataract surgery treated with intraoperative intracameral and postoperative topical nonsteroidal antiinflammatory drugs (NSAIDs) without steroids." | 1.56 | Rate of pseudophakic cystoid macular edema using intraoperative and topical nonsteroidal antiinflammatory drugs alone without steroids. ( Hess, J; Kauffman, L; Walter, K, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Walter, K | 1 |
| Kauffman, L | 1 |
| Hess, J | 1 |
| Grzybowski, A | 1 |
| Adamiec-Mroczek, J | 1 |
| Warren, KA | 1 |
| Bahrani, H | 1 |
| Fox, JE | 1 |
| Yilmaz, T | 1 |
| Cordero-Coma, M | 1 |
| Gallagher, MJ | 1 |
| Weisz, JM | 1 |
| Bressler, NM | 1 |
| Bressler, SB | 1 |
| Schachat, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery[NCT02646072] | Phase 4 | 80 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ketorolac and Pseudophakia
| Article | Year |
|---|---|
Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Humans; Ketorolac; Macu | 2012 |
2 trials available for ketorolac and Pseudophakia
| Article | Year |
|---|---|
NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodie | 2010 |
Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cataract Extraction; Chronic Disea | 1999 |
2 other studies available for ketorolac and Pseudophakia
| Article | Year |
|---|---|
Rate of pseudophakic cystoid macular edema using intraoperative and topical nonsteroidal antiinflammatory drugs alone without steroids.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2020 |
Topical Nonsteroidal Anti-inflammatory Drugs for Cystoid Macular Edema Prevention in Patients With Diabetic Retinopathy.
Topics: Administration, Ophthalmic; Anti-Inflammatory Agents, Non-Steroidal; Diabetic Retinopathy; Humans; K | 2017 |